A Phase 4 interventional study of Tranexamic acid and Normal Saline in Kidney Stones, Surgical Blood Loss and Percutaneous Nephrolithotomy, sponsored by Benha University. Completed at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Benha University · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies in Kidney Calculi with a site in Egypt — 21 open to participants now, 23 under way, none of them phase 3. Kidney Calculi · Egypt.
Among the 57 studies in Kidney Calculi with a site in Egypt, this one is the 32nd largest by enrollment of the 52 interventional ones that give a count, is one of 11 that started in 2025, is one of 2 in phase 4, and was the 50th registered.
510 studies on the registry are indexed under Kidney Calculi; 147 are open to participants now.
Browse Kidney Calculi studies →21 of the 57 studies in Kidney Calculi with a site in Egypt are open now. Recruiting first, the newest first:
Fayoum University Hospital · Sites in Egypt
Ages 6 mo–15 yrs
Beni-Suef University · Sites in Egypt
Ages 18+
Al-Azhar University · Sites in Egypt
Ages 18–70
Ain Shams University · Sites in Egypt
Ages 18–60
Helwan University · Sites in Egypt
Ages 18–70
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 88 Kidney Calculi studies recruiting now, 48 (55%) set no upper age limit and 23 (26%) stop at 75 or younger; 6 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 11 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 90 is close to the median of 86 across 392 interventional studies indexed under Kidney Calculi.
Median enrollment 100 across the 52 interventional studies, 100 across the 5 observational. Of the 24 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 57 have an industry lead sponsor. The 10 most frequent:
Benha University is the lead sponsor of 365 studies on the registry; 67 are open to participants now.
Benha University has 3 studies filed under Kidney Calculi — fewer than ten, so there is no comparison to draw.
6 of the studies in Kidney Calculi with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07295860Mansoura UniversityFANS-FURS vs Suction Mini-PCNL for 2-3 cm Renal Stones: A Multicenter Randomized Trial | 2027-01-01 |
| NCT07749807Benha UniversityNebulized Glubran 2-Assisted Tubeless PCNL Versus Conventional PCNL | 2027-02-01 |
| NCT07516535Ain Shams UniversityDISS vs FANS in Suction-Assisted RIRS for Medium-Sized Renal Stones | 2027-04-30 |
| NCT07939438Misr University for Science and TechnologyPostoperative Stenting After Flexible Ureteroscopy in Children With Upper Urinary Tract Stones | 2027-05-30 |
| NCT07689565Tanta UniversityStandard Versus Flexible and Navigable Suction Ureteral Access Sheath in Pediatric Flexible Ureterorenoscopy for Renal Stones < 2 cm | 2027-06-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 57 studies in Kidney Calculi with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Percutaneous nephrolithotomy is a minimally invasive surgical procedure used to remove large kidney stones. Although it is an effective treatment, bleeding during and after the procedure remains one of the main concerns and may sometimes require blood transfusion.
Tranexamic acid is a medication that helps reduce bleeding by limiting the breakdown of blood clots. It can be given through a vein and may also be used locally in irrigation fluid during surgery. This study evaluates whether using tranexamic acid by both routes during percutaneous nephrolithotomy can reduce blood loss, improve the clarity of the surgical field during endoscopy, and reduce the need for blood transfusion.
The study included adult patients with kidney stones larger than two centimeters who were suitable for percutaneous nephrolithotomy. Patients were randomly assigned to receive either tranexamic acid through a vein and in the irrigation fluid, or normal saline as a control treatment. Blood loss was assessed using hemoglobin and hematocrit levels before and after surgery, as well as hemoglobin concentration in the irrigation fluid collected at the end of the operation. The surgeon also assessed the clarity of the surgical field using a ten-point visual scale.
The hypothesis of the study is that combined intravenous and local administration of tranexamic acid in irrigation fluid during percutaneous nephrolithotomy reduces blood loss, improves surgical visibility, and lowers the need for blood transfusion compared with normal saline.
The criteria were revised on the registry on Oct 30, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this arm received tranexamic acid 10 milligrams per kilogram intravenously in 250 milliliters normal saline 15 minutes before induction of anesthesia, in addition to the same dose of tranexamic acid added to the first 4 liters of irrigation fluid during percutaneous nephrolithotomy.
Drug: Tranexamic acid
Participants in this arm received 250 milliliters normal saline intravenously 15 minutes before induction of anesthesia, in addition to normal saline placebo added to the first 4 liters of irrigation fluid during percutaneous nephrolithotomy.
Drug: Normal Saline
Tranexamic acid was administered as a combined intravenous and local intervention during percutaneous nephrolithotomy. The intravenous dose was given before anesthesia induction, and the local dose was added to the initial irrigation fluid used during the procedure.
Normal saline was used as the placebo comparator. It was administered intravenously before anesthesia induction and added to the initial irrigation fluid during percutaneous nephrolithotomy.
Change in hemoglobin concentration after percutaneous nephrolithotomy
Estimated intraoperative blood loss (mL) during percutaneous nephrolithotomy, calculated using the hemoglobin concentration measured in the collected and homogenized irrigation effluent and the total volume of collected fluid. All irrigation effluent, urethral catheter drainage, and blood clots were collected throughout the procedure, and a representative sample was analyzed for hemoglobin concentration. Lower estimated blood loss indicates less intraoperative bleeding.
Time frame: Intraoperatively, assessed at the end of surgery.
Change in Hematocrit After Percutaneous Nephrolithotomy
Change in hematocrit, expressed in percentage points, calculated as the difference between hematocrit measured within 24 hours before surgery and 24 hours after surgery. Negative values indicate a postoperative reduction in hematocrit.
Time frame: Within 24 hours preoperatively and at 24 hours postoperatively.
Need for blood transfusion
Number of participants requiring blood transfusion during or after percutaneous nephrolithotomy. Transfusion requirement was recorded according to the patient's clinical condition and laboratory findings.
Time frame: Intraoperatively and up to 24 hours postoperatively.
Hemoglobin concentration in irrigation fluid
Hemoglobin concentration measured in the irrigation fluid collected at the end of surgery as an estimate of intraoperative blood loss.
Time frame: At the end of surgery
Intraoperative Endoscopic Surgical Field Visibility Score
Endoscopic surgical field visibility was assessed by the operating surgeon at the end of percutaneous nephrolithotomy using a subjective 10-point numerical rating scale representing overall visualization throughout the procedure. Scores range from 1 (worst visibility) to 10 (best attainable visibility), with higher scores indicating better surgical field clarity. The scale has not been formally validated for percutaneous nephrolithotomy.
Time frame: At the end of surgery
Postoperative Hematuria
Number of participants who developed visible blood-stained urine after percutaneous nephrolithotomy.
Time frame: Up to 24 hours postoperatively
Number of Participants Requiring Additional Hemostatic Intervention
Number of participants requiring additional therapeutic or procedural intervention to control bleeding during or after percutaneous nephrolithotomy, beyond routine intraoperative hemostatic measures. Additional interventions were recorded according to the clinical and surgical documentation.
Time frame: Intraoperatively and up to 24 hours postoperatively.
Number of Participants With Postoperative Infection
Number of participants who developed postoperative infection after percutaneous nephrolithotomy.
Time frame: Up to 24 hours postoperatively
Postoperative Hematuria
Number of participants with visible hematuria requiring continued nephrostomy tube closure or delayed nephrostomy tube removal.
Time frame: Up to 24 hours postoperatively
Change in Hemoglobin Concentration
Change in Hemoglobin Concentration After Percutaneous Nephrolithotomy Description: Change in blood hemoglobin concentration (g/dL), calculated as the difference between hemoglobin measured within 24 hours before surgery and 24 hours after surgery. Negative values indicate a postoperative reduction in hemoglobin concentration.
Time frame: Within 24 hours preoperatively and at 24 hours postoperatively.
Total Intraoperative Irrigation Fluid Volume
Total volume of irrigation fluid used during percutaneous nephrolithotomy, measured in liters (L). Irrigation volume was recorded throughout the procedure for each participant.
Time frame: Intraoperatively, assessed at the end of surgery.
Number of Participants With Residual Renal Stones Following Percutaneous Nephrolithotomy
Number of participants with residual renal stones identified during postoperative assessment following percutaneous nephrolithotomy. Residual stone status and the requirement for subsequent stone-management procedures were recorded.
Time frame: 24 hours postoperatively
Postoperative Length of Hospital Stay
Duration of postoperative hospitalization, measured in days from the date of percutaneous nephrolithotomy to hospital discharge.
Time frame: From the day of surgery until hospital discharge (postoperative days 1-3).
Postoperative Fever
Number of participants who developed documented postoperative fever following percutaneous nephrolithotomy, based on postoperative temperature monitoring and clinical records. Fever was recorded separately from confirmed postoperative infection.
Time frame: From completion of surgery through 24 hours postoperatively
Plan to share: Yes — Deidentified individual participant data related to the study outcomes will be available for sharing. The shared data may include baseline characteristics, operative data, hemoglobin and hematocrit measurements, blood transfusion data, irrigation fluid hemoglobin concentration, surgical field visibility score, and recorded postoperative outcomes.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Data will become available beginning 6 months after publication of the study results and will remain available for 2 years.
Access criteria: Data will be available upon reasonable request from qualified researchers for scientific purposes. Requests will be reviewed by the study investigators, and data will be shared after approval and completion of a data use agreement.
No publications or documents are linked to this record.
Ran from Jun 2025 to primary completion in Feb 2026, 7 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: start May 2025 → Jun 2025, primary completion Apr 2026 → Feb 2026 and completion Apr 2026 → Feb 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tranexamic Acid